

Anti-Mumps-Virus ELISA (IgM)

Test instruction















ORDER NO.	ANTIBODIES AGAINST	IG CLASS	SUBSTRATE	FORMAT
EI 2630-9601 M	Mumps virus	IgM	Ag-coated microplate wells	96 x 01 (96)

Indication: The ELISA test kit provides a semiquantitative in vitro assay for human antibodies of the IgM class against mumps virus in serum or plasma for the diagnosis of mumps.

Application: The Anti-Mumps-Virus ELISA (IgM) is based on highly purified cell lysate infected with mumps virus of the strain "Enders" (ATCC VR-106). In the serological diagnostics of acute mumps, this ELISA enables the reliable detection of pathogen-specific antibodies of class IgM. It must be taken into account that specific IgM antibodies in mumps infections are frequently not repeatedly produced in persons who are vaccinated (breakthrough infection). Alongside serological investigations, also direct pathogen detection using PCR can be performed for the diagnosis of acute infection.

Principles of the test: The test kit contains microtiter strips each with 8 break-off reagent wells coated with mumps antigens. In the first reaction step, diluted patient samples are incubated in the wells. In the case of positive samples, specific IgM antibodies (also IgA and IgG) will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled anti-human IgM (enzyme conjugate) catalysing a colour reaction.


Contents of the test kit:

Component	Colour	Format	Symbol
1. Microplate wells coated with antigens 12 microplate strips each containing 8 individual break-off wells in a frame, ready for use	---	12 x 8	
2. Calibrator (IgM, human), ready for use	dark red	1 x 2.0 ml	
3. Positive control (IgM, human), ready for use	blue	1 x 2.0 ml	
4. Negative control (IgM, human), ready for use	green	1 x 2.0 ml	
5. Enzyme conjugate peroxidase-labelled anti-human IgM (goat), ready for use	red	1 x 12 ml	
6. Sample buffer containing IgG/RF absorbent (anti-human IgG antibody preparation obtained from goat), ready for use	green	1 x 100 ml	
7. Wash buffer 10x concentrate	colourless	1 x 100 ml	
8. Chromogen/substrate solution TMB/H ₂ O ₂ , ready for use	colourless	1 x 12 ml	
9. Stop solution 0.5 M sulphuric acid, ready for use	colourless	1 x 12 ml	
10. Test instruction	---	1 booklet	
11. Quality control certificate	---	1 protocol	
 Lot description			 Storage temperature
 In vitro diagnostic medical device			 Unopened usable until



Preparation and stability of the reagents

Note: All reagents must be brought to room temperature (+18°C to +25°C) approx. 30 minutes before use. After first use, the reagents are stable until the indicated expiry date if stored at +2°C to +8°C and protected from contamination, unless stated otherwise below.

- **Coated wells:** Ready for use. Tear open the resealable protective wrapping of the microplate at the recesses above the grip seam. Do not open until the microplate has reached room temperature to prevent the individual strips from moistening. Immediately replace the remaining wells of a partly used microplate in the protective wrapping and tightly seal with the integrated grip seam (Do not remove the desiccant bags).
Once the protective wrapping has been opened for the first time, the wells coated with antigens can be stored in a dry place and at a temperature between +2°C and +8°C for 4 months.
- **Calibrator and controls:** Ready for use. The reagents must be mixed thoroughly before use.
- **Enzyme conjugate:** Ready for use. The enzyme conjugate must be mixed thoroughly before use.
- **Sample buffer:** Ready for use. The green coloured sample buffer contains IgG/RF absorbent. Serum or plasma samples diluted with this sample buffer are only to be used for the determination of IgM antibodies.
- **Wash buffer:** The wash buffer is a 10x concentrate. If crystallisation occurs in the concentrated buffer, warm it to 37°C and mix well before diluting. The quantity required should be removed from the bottle using a clean pipette and diluted with deionised or distilled water (1 part reagent plus 9 parts distilled water).
For example: For 1 microplate strip, 5 ml concentrate plus 45 ml water.
The working strength wash buffer is stable for 4 weeks when stored at +2°C to +8°C and handled properly.
- **Chromogen/substrate solution:** Ready for use. Close the bottle immediately after use, as the contents are sensitive to light . The chromogen/substrate solution must be clear on use. Do not use the solution if it is blue coloured.
- **Stop solution:** Ready for use.

Storage and stability: The test kit has to be stored at a temperature between +2°C to +8°C. Do not freeze. Unopened, all test kit components are stable until the indicated expiry date.

Waste disposal: Patient samples, calibrators, controls and incubated microplate strips should be handled as infectious waste. All reagents must be disposed of in accordance with local disposal regulations.

Warning: The calibrator and controls of human origin have tested negative for HBsAg, anti-HCV, anti-HIV-1 and anti-HIV-2. Nonetheless, all materials should be treated as being a potential infection hazard and should be handled with care. Some of the reagents contain the agent sodium azide in a non-declarable concentration. Avoid skin contact.



Preparation and stability of the patient samples

Samples: Human serum or EDTA, heparin or citrate plasma.

Stability: **Patient samples** to be investigated can generally be stored at +2°C to +8°C for up to 14 days. Diluted samples should be incubated within one working day.

Introduction: Before the determination of specific antibodies of class IgM, antibodies of class IgG should be removed from the patient sample. This procedure must be carried out in order to prevent any rheumatoid factors of class IgM from reacting with specifically bound IgG, which would lead to false positive IgM test results, and to prevent specific IgG displacing IgM from the antigen, which would lead to false IgM-negative test results.

Functional principle: The sample buffer (green coloured!) contains an anti-human antibody preparation from goat. IgG from a serum sample is bound with high specificity by these antibodies and precipitated. If the sample also contains rheumatoid factors, these will be absorbed by the IgG/anti-human IgG complex.

Separation properties:

- All IgG subclasses are bound and precipitated by the anti-human IgG antibodies.
- Human serum IgG in concentrations of up to 15 mg per ml are removed (average serum IgG concentration in adults: 12 mg per ml).
- Rheumatoid factors are also removed.
- The recovery rate of the IgM fraction is almost 100%.

Performance: The **patient samples** for analysis are diluted **1:101** with green coloured sample buffer. For example, add 10 µl sample to 1.0 ml sample buffer and mix well by vortexing. Sample pipettes are not suitable for mixing. Incubate the mixture for at least **10 minutes** at room temperature (+18°C to +25°C). Subsequently, it can be pipetted into the microplate wells according to the pipetting protocol.

Notes:

- Antibodies of the class IgG should not be analysed with this mixture.
- It is possible to check the efficacy of the IgG/RF absorbent for an individual patient sample by performing an IgG test in parallel to the IgM test using the mixture. If the IgG test is negative, the IgM result can be considered as reliable.
- The calibrator and controls are ready for use, do not dilute them.



Incubation

(Partly) manual test performance

Sample incubation:
(1st step)

Transfer 100 µl of the calibrator, positive and negative controls or diluted patient samples into the individual microplate wells according to the pipetting protocol. Incubate for **30 minutes** at room temperature (+18°C to +25°C).

Washing:

Manual: Empty the wells and subsequently wash 3 times using 300 µl of working strength wash buffer for each wash.

Automatic: Wash the reagent wells 3 times with 450 µl of working strength wash buffer (program setting: e.g. TECAN Columbus Washer "Overflow Mode").

Leave the wash buffer in each well for 30 to 60 seconds per washing cycle, then empty the wells. After washing (manual and automated tests), thoroughly dispose of all liquid from the microplate by tapping it on absorbent paper with the openings facing downwards to remove all residual wash buffer.

Note: Residual liquid (>10 µl) in the reagent wells after washing can interfere with the substrate and lead to false low extinction values.

Insufficient washing (e.g. less than 3 wash cycles, too small wash buffer volumes, or too short residence times) can lead to false high extinction values.

Free positions on the microplate strip should be filled with blank wells of the same plate format as that of the parameter to be investigated.

Conjugate incubation:
(2nd step)

Pipette 100 µl of enzyme conjugate (peroxidase-labelled anti-human IgM) into each of the microplate wells. Incubate for **30 minutes** at room temperature (+18°C to +25°C).

Washing:

Empty the wells. Wash as described above.

Substrate incubation:
(3rd step)

Pipette 100 µl of chromogen/substrate solution into each of the microplate wells. Incubate for **15 minutes** at room temperature (+18°C to +25°C) (protect from direct sunlight).

Stopping:

Pipette 100 µl of stop solution into each of the microplate wells in the same order and at the same speed as the chromogen/substrate solution was introduced.

Measurement:

Photometric measurement of the colour intensity should be made at a **wavelength of 450 nm** and a reference wavelength between 620 nm and 650 nm **within 30 minutes of adding the stop solution**. Prior to measuring, slightly shake the microplate to ensure a homogeneous distribution of the solution.

Test performance using fully automated analysis devices

Sample dilution and test performance are carried out fully automatically using an analysis device. The incubation conditions programmed in the respective software authorised by EUROIMMUN may deviate slightly from the specifications given in the ELISA test instruction. However, these conditions were validated in respect of the combination of the EUROIMMUN Analyzer I, Analyzer I-2P or the DSX from Dynex and this EUROIMMUN ELISA. Validation documents are available on enquiry.

Automated test performance using other fully automated, open system analysis devices is possible. However, the combination should be validated by the user.



Pipetting protocol

	1	2	3	4	5	6	7	8	9	10	11	12
A	C	P 6	P 14	P 22								
B	pos.	P 7	P 15	P 23								
C	neg.	P 8	P 16	P 24								
D	P 1	P 9	P 17									
E	P 2	P 10	P 18									
F	P 3	P 11	P 19									
G	P 4	P 12	P 20									
H	P 5	P 13	P 21									

The above pipetting protocol is an example of the **semiquantitative analysis** of antibodies in 24 patient samples (P 1 to P 24).

Calibrator (C), positive (pos.) and negative (neg.) control as well as the patient samples have been incubated in one well each. The reliability of the ELISA test can be improved by duplicate determinations of each sample.

The wells can be broken off individually from the strips. This makes it possible to adjust the number of test substrates used to the number of samples to be examined and minimises reagent wastage.

Both positive and negative controls serve as internal controls for the reliability of the test procedure. They should be assayed with each test run.

Calculation of results

The extinction value of the calibrator defines the upper limit of the reference range of non-infected persons (**cut-off**) recommended by EUROIMMUN. Values above the indicated cut-off are to be considered as positive, those below as negative.

Semiquantitative: Results can be evaluated semiquantitatively by calculating a ratio of the extinction value of the control or patient sample over the extinction value of calibrator. Use the following formula to calculate the ratio:

$$\frac{\text{Extinction of the control or patient sample}}{\text{Extinction of calibrator}} = \text{Ratio}$$

EUROIMMUN recommends interpreting results as follows:

Ratio <0.8:	negative
Ratio ≥0.8 to <1.1:	borderline
Ratio ≥1.1:	positive

For duplicate determinations the mean of the two values should be taken. If the two values deviate substantially from one another, EUROIMMUN recommends to retest the samples.

A negative serological result does not exclude an infection. Particularly in the early phase of an infection, antibodies may not yet be present or are only present in such small quantities that they are not detectable. In case of a borderline result, a secure evaluation is not possible. If there is a clinical suspicion and a negative test result, we recommend clarification by means of other diagnostic methods and/or the serological investigation of a follow-up sample. A positive result indicates that there has been contact with the pathogen. In the determination of pathogen-specific IgM antibodies, polyclonal stimulation of the immune system or antibody persistence may affect the diagnostic relevance of positive findings. Significant titer increases (exceeding factor 2) and/or seroconversion in a follow-up sample taken after 7-10 days can indicate an acute infection. To investigate titer changes, sample and follow-up sample should be incubated in adjacent wells of the ELISA microplate within the same test run. For diagnosis, the clinical picture of the patient always needs to be taken into account along with the serological findings.



Test characteristics

Calibration: As no international reference serum exists for the detection of IgM antibodies against mumps virus, results are provided in the form of ratios which are a relative measure for the concentration of antibodies in serum or plasma.

For every group of tests performed, the extinction values of the calibrator and the ratios of the positive and negative controls must lie within the limits stated for the relevant test kit lot. A quality control certificate containing these reference values is included. If the values specified for the controls are not achieved, the test results may be inaccurate and the test should be repeated.

The binding activity of the antibodies and the activity of the enzyme used are temperature-dependent. It is therefore recommended using a thermostat in all three incubation steps. The higher the room temperature (+18°C to +25°C) during the incubation steps, the greater will be the extinction values. Corresponding variations apply also to the incubation times. However, the calibrator is subject to the same influences, with the result that such variations will be largely compensated in the calculation of the result.

Antigen: The antigen source is provided by inactivated cell lysates of Vero cells infected with the "Enders" strain of mumps virus.

Detection limit: The lower detection limit is defined as the mean value of an analyte-free sample plus three times the standard deviation and is the smallest detectable antibody titer. The lower detection limit of the Anti-Mumps-Virus ELISA (IgM) is ratio 0.03.

Cross reactivity: The quality of the antigen used ensures a high specificity of the ELISA. Sera from patients with infections caused by various agents were investigated with the Anti-Mumps-Virus ELISA (IgM).

Antibodies against	n	Anti-Mumps virus positive
Borrelia	10	0%
CMV	9	0%
EBV	21	33%
EBV CA	10	20%
Measles virus	7	0%
Parvo B19	10	10%
Rubella virus	10	10%
TBE	10	0%
Toxoplasma	10	0%
VZV	5	20%

Cross reactivities to other respiratory viruses cannot be excluded. The ELISA is designed as a screening test with maximum sensitivity.

Interference: Haemolytic, lipaemic and icteric samples showed no influence on the result up to a concentration of 10 mg/ml for haemoglobin, 20 mg/ml for triglycerides and 0.4 mg/ml for bilirubin in this ELISA.

Reproducibility: The reproducibility of the test was investigated by determining the intra- and inter-assay coefficients of variation (CV) using 3 sera. The intra-assay CVs are based on 20 determinations and the inter-assay CVs on 4 determinations performed in 6 different test runs.

<i>Intra-assay variation, n = 20</i>		
Serum	Mean value (Ratio)	CV (%)
1	0.9	7.9
2	2.8	3.4
3	3.5	6.5

<i>Inter-assay variation, n = 4 x 6</i>		
Serum	Mean value (Ratio)	CV (%)
1	1.0	7.9
2	3.2	8.5
3	4.2	8.2



Specificity and sensitivity: 70 clinically characterised patient samples (interlaboratory test samples from INSTAND, Germany) were examined with the EUROIMMUN Anti-Mumps-Virus ELISA (IgM). The test showed a specificity of 98.4% and a sensitivity of 100%.

n = 70		INSTAND		
		positiv	borderline	negativ
ELISA	positiv	4	0	1
	borderline	0	0	2
	negativ	0	0	63

Reference range: The levels of anti-mumps virus antibodies (IgM) were analysed with this EUROIMMUN ELISA in a panel of 500 healthy blood donors. With a cut-off ratio of 1.0, 1.2% of the blood donors were anti-mumps virus positive (IgM).

Clinical significance

The mumps virus (MV) causes an acute, feverish general infection which occurs mainly in childhood and is very infectious. The infection is characterised by an inflammatory swelling of the parotid gland. Frequently involved are also pancreas, testes, ovaries and the central nervous system.

Postpubertal mumps in males not immunised as children is associated with a 40% incidence of orchitis. Clinicians should be aware that epididymo-orchitis may be secondary to mumps infection even with no history or clinical evidence of parotitis.

Mumps virus is a highly neurotropic virus with evidence of central nervous system invasion (CNS) in approximately half of all cases of infection. Hydrocephalus secondary to mumps is relatively rare. The mumps virus can be the aetiology of secondary autoimmune thrombocytopenic purpura. Additional complications of mumps are keratitis and/or iritis.

Antibodies against the mumps virus can be detected in the serum of nearly all patients after the illness has taken its course. Specific IgM and IgG antibodies to mumps virus are detected in sera of mumps patients by Enzyme Linked Immunosorbent Assay (ELISA) in agreement with the results obtained by Indirect Immunofluorescence Test (IIFT). Mumps IgM antibodies can be demonstrated in all patients with serologically verified and clinically typical (parotitis, meningitis, or orchitis) mumps virus infection.

IgM antibodies develop soon after the onset of symptoms; most patients have IgM antibodies from the second day, and the highest titers are reached within the first week. The antibody response in mumps parotitis does not differ from that in mumps meningitis/encephalitis, while relatively higher antibody titers are found in patients with orchitis/epididymitis. Mumps IgM ELISA (also IgG) and IIFT are more rapid and sensitive for the serological diagnosis of mumps infection than e.g. haemagglutination inhibition test (HI) and complement fixation (CF). Mumps virus infections often raise heterologous antibodies.

In mumps meningitis/encephalitis agent-specific antibodies of class IgG are produced in CSF. The intrathecal agent-specific antibody production is defined by the relative CSF/serum quotient CSQ_{rel} (synonym: antibody specificity index). The quotient is calculated from the amount of agent-specific antibodies in total CSF IgG in proportion to the amount of agent-specific antibodies in total serum IgG.

Active immunisation of seronegative children is recommended in view of the complications which can develop. Neutralisation activity and persistence of antibodies are induced in response to vaccination of 12- to 24-month-old infants. Subsequently, antibody titers and neutralising activity can be determined using ELISA and IIFT, with the highest prevalence at the earliest 120 days after vaccination. Test systems used both for monitoring the immunisation status and for serological diagnosis of the infection should be based on a combination of wild type and vaccination strain antigens. Life-long immunity is normally developed. However, antibody levels are 8 to 10 times lower in postvaccination sera than in convalescent sera.

Literature references

1. Briggs CM, Mayer AE, Parks GD. **Mumps virus inhibits migration of primary human macrophages toward a chemokine gradient through a TNF-alpha dependent mechanism.** Virology 422 (2012) 245-252.
2. Centers for Disease Control and Prevention (CDC). **Mumps outbreak on a university campus – california, 2011.** MMWR Morb Mortal Wkly Rep 61 (2012) 986-989.
3. EUROIMMUN AG. **Testkit für die Labordiagnostik.** Deutsches Gebrauchsmuster DE 20 2012 004 404 (angemeldet 2012).
4. Krause CH, Eastick K, Ogilvie MM. **Real-time PCR for mumps diagnosis on clinical specimens--comparison with results of conventional methods of virus detection and nested PCR.** J Clin Virol 37 (2006) 184-189.
5. EUROIMMUN AG. Morrin M. **Vorrichtung und Verfahren zur automatischen Fokussierung für die Mikroskopie schwach leuchtender Substrate.** Deutsche und Internationale Patentanmeldung DE 10 2010 035 104.0 (angemeldet 2010) und WO 2012/025220 (angemeldet 2011).
6. Philip J, Selvan D, Desmond AD. **Mumps orchitis in the non-immune postpubertal male: a resurgent threat to male fertility?** BJU Int 97 (2006) 138-141.
7. Reiber H, Peter JB. **Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.** J Neurol Sci 184 (2001) 101-122.
8. Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P. **Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.** Pediatr Infect Dis 27 (2008) 724-730.
9. Sheek-Hussein M, Hashmey R, Alsuwaidi AR, Al Maskari F, Amiri L, Souid AK. **Seroprevalence of measles, mumps, rubella, varicella--zoster and hepatitis A--C in Emirati medical students.** BMC Public Health 12 (2012) 1047.
10. Smits GP, van Gageldonk PG, Schouls LM, van der Klis FR, Berbers GA. **Development of a bead-based multiplex immunoassay for simultaneous quantitative detection of IgG serum antibodies against measles, mumps, rubella, and varicella-zoster virus.** Clin Vaccine Immunol 19 (2012) 396-400.
11. Steinhagen* K, Biermann-Göcke S, Dönig M, Zein M, Wanderinger* KP, Schlumberger* W, Stöcker* W. (*EUROIMMUN AG). **Mumps-spezifische Immunität etabliert sich erst 120 Tage nach MMR-Impfung! Antikörper-Bestimmung unter Verwendung von Antigenen des Impfstammes anstelle des Wildtyps.** 104. Jahrestagung der Deutschen Gesellschaft für Kinder- und Jugendmedizin (DGKJ), München (2008) und Abstract zur 16. Jahrestagung der Deutschen Gesellschaft für Pädiatrische Infektiologie (DGPI), Erlangen (2008).
12. EUROIMMUN AG. Stöcker W, Ehling T. **Vorrichtung und Verfahren zur Untersuchung einer biologischen Probe.** Deutsche Patentanmeldung DE 10 2011 011 795.4 (angemeldet 2011).
13. Stöcker* W, Fauer* H, Krause* C, Barth E, Martinez A. (*EUROIMMUN AG). **Verfahren zur Optimierung der automatischen Fluoreszenzerkennung in der Immundiagnostik.** Deutsche Patentanmeldung (Offenlegungsschrift) DE 10 2006 027 516.0 und WO2007140952 (2006).